Phase Ib/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Refractory/Recurrent Primary (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL)
| Autor: | Grommes, Christian 1, Piotrowski, Anna 2, *, Pentsova, Elena 2, *, Gavrilovic, Igor 3, *, Stone, Jacqueline B 3, *, Lin, Andrew 2, *, Wongchai, Venissala 2, *, Madzsar, Juli T 3, *, Malani, Rachna 2, *, Nolan, Craig 2, *, Francis, Jasmine 2, *, DeAngelis, Lisa 4, *, Schaff, Lauren 3, *, Mellinghoff, Ingo K 5, * |
|---|---|
| Zdroj: | In Blood 15 November 2022 140 Supplement 1:3807-3808 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|